Hengrui Pharmaceuticals Completes Sale, Transfer of Unlocked Shares in 2025 Share Placement Plan

MT Newswires Live07:36

Jiangsu Hengrui Pharmaceuticals (SHA:600276, HKG:1276) completed the sale and transfer of all unlocked shares under its 2025 share placement plan, according to a Shanghai bourse filing over the weekend.

About 4.7 million shares, or 0.07% of the pharmaceutical company's total share capital, were unlocked after the first lock-up period expired on Nov. 7.

Around 2.8 million shares were transferred through the company's employee stock ownership plan, while 1.9 million shares were sold through centralized bidding.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment